Bnp (1-32) epitope and antibodies directed against said epitope

Patent metadata

Field	Value
Publication number	US-2020072853-A1
Application number	US-201916684618-A
Country	US
Kind code	A1
Filing date	Nov 15, 2019
Priority date	Aug 3, 2007
Publication date	Mar 5, 2020
Grant date	—

Abstract

The present invention relates to a polypeptide carrying a human BNP(1-32) epitope according to Formula (I): a1-R1-X1-FGRKMDR-X2-R2-a2 as well as ligands specific of the FGRKMDR epitope.

First claim

We claim:

1 . A method for measuring, in a biological sample, the concentration of human BNP(1-32) or a derivative of human proBNP(1-108) containing the sequence FGRKMDR, comprising:
1) contacting the biological sample with at least one ligand specific of an epitope of the sequence FGRKMDR under conditions allowing the formation of antigen-ligand complexes, and 2) detecting any complex which may have formed; and 3) determining the concentration of human BNP(1-32) or a derivative of human proBNP(1-108) containing the sequence FGRKMDR in the sample.

2 . The method according to claim 1 , comprising at least one additional step of contacting the biological sample with at least one additional ligand specific of human BNP(1-32), human proBNP(1-108) or the respective fragments thereof, and having a different specificity from that of the ligand specific of an epitope of the sequence FGRKMDR.

3 . The method according to claim 2 , wherein the additional ligand is an antibody.

4 . A method of diagnosis, prognosis, risk stratification or therapeutic follow-up of at least one cardiac and/or vascular pathology in an individual, comprising the following steps of:
1) contacting a biological sample from the individual with at least one ligand specific of an epitope of the sequence FGRKMDR under conditions allowing the formation of antigen-ligand complexes, 2) detecting any complex which may have formed, and 3) based on the result of the detection in step 2, determining a diagnosis, a prognosis, a risk of the development or therapeutic follow-up of the pathology in the individual.

5 . The method according to claim 4 , comprising at least one additional step of contacting the biological sample with at least one additional ligand specific of human BNP(1-32), human proBNP(1-108) or the respective fragments thereof, and having a different specificity from that of the ligand specific of an epitope of the sequence FGRKMDR.

6 . The method according to claim 5 , wherein the additional ligand is an antibody.

7 . The method according to claim 4 , wherein the pathology is selected from the group comprising:
congestive heart failure, acute coronary syndrome, cerebrovascular accident, kidney failure, dyspnea, high blood pressure, atheromatous plaque rupture, patent ductus arteriosus in premature newborns, and/or diabetis.

Assignees

• Bio Rad Europe Gmbh
• Centre Nat Rech Scient

Inventors

• Rieunier Francois
• Giuliani Isabelle
• Villard-Saussine Sylvie

Classifications

• G01N33/74 Primary

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N2800/324

  Coronary artery diseases, e.g. angina pectoris, myocardial infarction · CPC title

• G01N2333/58

  Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin · CPC title

• G01N2800/32

  Cardiovascular disorders · CPC title